Lista de obras -

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

artículo científico publicado en 2010

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

artículo científico publicado en 2008

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

artículo científico publicado en 2016

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

artículo científico publicado en 2016

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report

artículo científico publicado en 2010

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

artículo científico publicado en 2013

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

artículo científico publicado en 2013

Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer

artículo científico publicado en 2021

Ceritinib in ALK-rearranged non-small-cell lung cancer

artículo científico publicado en 2014

Characteristics of lung cancers harboring NRAS mutations

artículo científico publicado en 2013

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

artículo científico publicado en 2015

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

artículo científico publicado en 2006

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

artículo científico publicado en 2009

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

artículo científico publicado en 2014

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

artículo científico publicado en 2013

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

artículo científico publicado en 2012

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

artículo científico publicado en 2014

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

artículo científico publicado en 2008

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

artículo científico publicado en 2011

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

artículo científico publicado en 2008

Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.

artículo científico publicado en 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

artículo científico publicado en 2005

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

artículo científico publicado en 2012

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

artículo científico publicado en 2007

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

artículo científico

Management and outcomes of relapse after treatment for thymoma and thymic carcinoma.

artículo científico publicado en 2011

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

artículo científico publicado en 2008

Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy?

scientific article published on 01 February 2008

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

artículo científico publicado en 2006

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

artículo científico publicado en 2015

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

artículo científico publicado en 2011

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

artículo científico publicado en 2006

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

artículo científico publicado en 2018

Lista de obras de

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

Automated NLP Extraction of Clinical Rationale for Treatment Discontinuation in Breast Cancer

Ceritinib in ALK-rearranged non-small-cell lung cancer

Characteristics of lung cancers harboring NRAS mutations

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

Management and outcomes of relapse after treatment for thymoma and thymic carcinoma.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy?

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.